Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).

Unger JM, Griffin K, Donaldson GW, Baranowski KM, Good MJ, Reburiano E, Hussain M, Monk PJ, Van Veldhuizen PJ, Carducci MA, Higano CS, Lara PN, Tangen CM, Quinn DI, Wade JL III, Vogelzang NJ, Thompson IM Jr, Moinpour CM

Open source

DOI: 10.1186/s41687-018-0054-5
Published: 2017
Container: Journal of patient-reported outcomes
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s41687-018-0054-5,
  title = {Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).},
  author = {Unger JM and Griffin K and Donaldson GW and Baranowski KM and Good MJ and Reburiano E and Hussain M and Monk PJ and Van Veldhuizen PJ and Carducci MA and Higano CS and Lara PN and Tangen CM and Quinn DI and Wade JL III and Vogelzang NJ and Thompson IM Jr and Moinpour CM},
  year = {2017},
  journal = {Journal of patient-reported outcomes},
  doi = {10.1186/s41687-018-0054-5},
  url = {https://doi.org/10.1186/s41687-018-0054-5}
}

RIS

TY  - JOUR
TI  - Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).
AU  - Unger JM
AU  - Griffin K
AU  - Donaldson GW
AU  - Baranowski KM
AU  - Good MJ
AU  - Reburiano E
AU  - Hussain M
AU  - Monk PJ
AU  - Van Veldhuizen PJ
AU  - Carducci MA
AU  - Higano CS
AU  - Lara PN
AU  - Tangen CM
AU  - Quinn DI
AU  - Wade JL III
AU  - Vogelzang NJ
AU  - Thompson IM Jr
AU  - Moinpour CM
PY  - 2017
JO  - Journal of patient-reported outcomes
DO  - 10.1186/s41687-018-0054-5
UR  - https://doi.org/10.1186/s41687-018-0054-5
ER  -

APA

JM, U., K, G., GW, D., KM, B., MJ, G., E, R., M, H., PJ, M., PJ, V. V., MA, C., CS, H., PN, L., CM, T., DI, Q., III, W. J., NJ, V., Jr, T. I., & CM, M. (2017). Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).. Journal of patient-reported outcomes. https://doi.org/10.1186/s41687-018-0054-5

Source records

pubmed · retrieved 2026-09-25T23:11:41.882Z